The Tyr Phenomenon: A Hypocalcemic Response in High-Volume Treatment Responders to<sup>177</sup>Lu-Prostate-Specific Membrane Antigen Therapy-Reference-Cited by-同舟云学术

The Tyr Phenomenon: A Hypocalcemic Response in High-Volume Treatment Responders to¹⁷⁷Lu-Prostate-Specific Membrane Antigen Therapy

Published:2023-06-22 Issue:9 Volume:64 Page:1412-1416
ISSN:0161-5505
Container-title:Journal of Nuclear Medicine
language:en
Short-container-title:J Nucl Med

Author:

Kumar Shejil,Crumbaker Megan,Harvey Christopher,Pathmanandavel Sarennya,John Nikieth,Swiha Mina M.,McDonald Michelle M.,Clifton-Bligh Roderick,Lee Adrian,Bastick Patricia,Counter William,Nguyen Andrew,Emmett Louise

Publisher

Society of Nuclear Medicine

Subject

Radiology, Nuclear Medicine and imaging

Reference9 articles.

1. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial;Hofman;Lancet.,2021

2. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

3. Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT);Emmett;Ther Adv Med Oncol.,2023

4. Use of bone turnover markers in postmenopausal osteoporosis;Eastell;Lancet Diabetes Endocrinol.,2017

5. The pharmacokinetics and pharmacodynamics of denosumab in patients with advanced solid tumours and bone metastases: a systematic review;Sohn;Br J Clin Pharmacol.,2014

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PSMA-based therapeutics for prostate cancer;Expert Opinion on Pharmacotherapy;2024-07-02

2. Reply: Unraveling the Hypocalcemic Response to¹⁷⁷Lu-Prostate-Specific Membrane Antigen Therapy;Journal of Nuclear Medicine;2024-02

3. Denosumab/lutetium-177-psma-imaging-and-therapy;Reactions Weekly;2023-12-16

4. Unraveling the Hypocalcemic Response to¹⁷⁷Lu-Prostate-Specific Membrane Antigen Therapy;Journal of Nuclear Medicine;2023-09-21